Evidence map›Paper›PMID 34645815›Full record

ArticleNature communications2021

BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.

Zhihua Kang, Pan Fu, Allen L Alcivar, Haiqing Fu, Christophe Redon, Tzeh Keong Foo, Yamei Zuo, Caiyong Ye, Ryan Baxley, Advaitha Madireddy and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Zhihua KangDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0001-8153-8846
Pan Fu *Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0003-2587-4348
Allen L Alcivar *Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Haiqing FuDevelopmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-4764-1422
Christophe RedonDevelopmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Tzeh Keong FooDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0003-0168-7054
Yamei ZuoDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0002-4201-3577
Caiyong YeDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Ryan BaxleyDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3286-7990
Advaitha MadireddyDepartment of Pediatric Hematology/Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0002-4730-5325
Remi BuissonMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7196-8209
Anja-Katrin BielinskyDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-1783-619X
Lee ZouMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3094-1058
Zhiyuan ShenDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID 0000-0003-2834-0309
Mirit I AladjemDevelopmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-1875-3110
Bing XiaDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. xiabi@cinj.rutgers.edu.ORCID 0000-0003-3259-6139
Rutgers, The State University of New Jersey · USNational Cancer Institute · USHarvard University · USUniversity of Minnesota · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Project 4: The BRCA Network in Medulloblastoma Responses to Replication StressP01CA250957 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI XIA, BING · 2021 to 2025
$11.3M
Role of PALB2 in the DNA Damage Response and Cancer SuppressionR01CA138804 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI XIA, BING · 2009 to 2024
$5.5M
Molecular modulators of radiation-induced chromosome instability and hematopoietic damageR01CA195612 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI SHEN, ZHIYUAN · 2015 to 2025
$3.6M
Mechanistic insight into genome stability pathwaysR35GM141805 · NIGMS · UNIVERSITY OF VIRGINIA · PI Anja-Katrin Bielinsky · 2021 to 2026
$2.9M
Molecular Mechanisms of APOBEC-Induced Mutagenesis in CancerR37CA252081 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2021 to 2026
$2.5M
Regulation of DNA replication kinetics by BRCA2 after DNA damageR01CA262227 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI XIA, BING · 2021 to 2025
$1.7M
TARGETING APOBEC3A-EXPRESSING CANCER CELLS WITH ATR INHIBITORSR00CA212154 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUISSON, REMI · 2018 to 2020
$747k
NCI NIH HHS P01 CA250957NCI NIH HHS P30 CA072720NCI NIH HHS R00 CA212154NCI NIH HHS R01 CA138804NCI NIH HHS R01 CA195612NCI NIH HHS R01 CA262227NCI NIH HHS R37 CA252081NIGMS NIH HHS R35 GM141805
6 · The paper itself

Abstract

The BRCA2 tumor suppressor protects genome integrity by promoting homologous recombination-based repair of DNA breaks, stability of stalled DNA replication forks and DNA damage-induced cell cycle checkpoints. BRCA2 deficient cells display the radio-resistant DNA synthesis (RDS) phenotype, however the mechanism has remained elusive. Here we show that cells without BRCA2 are unable to sufficiently restrain DNA replication fork progression after DNA damage, and the underrestrained fork progression is due primarily to Primase-Polymerase (PRIMPOL)-mediated repriming of DNA synthesis downstream of lesions, leaving behind single-stranded DNA gaps. Moreover, we find that BRCA2 associates with the essential DNA replication factor MCM10 and this association suppresses PRIMPOL-mediated repriming and ssDNA gap formation, while having no impact on the stability of stalled replication forks. Our findings establish an important function for BRCA2, provide insights into replication fork control during the DNA damage response, and may have implications in tumor suppression and therapy response.

Indexed as

Recombinational DNA RepairBRCA2 ProteinCell Line, TumorCell SurvivalDNA-Binding ProteinsDNA DamageDNA-Directed DNA PolymeraseDNA HelicasesDNA, NeoplasmDNA PrimaseDNA ReplicationDNA, Single-StrandedGene Expression Regulation, NeoplasticGenomic InstabilityHEK293 CellsHeLa CellsBRCA2 ProteinBRCA2 protein, humanDNA-Binding ProteinsDNA-Directed DNA PolymeraseDNA HelicasesDNA, NeoplasmDNA PrimaseDNA, Single-StrandedHLTF protein, humanMCM10 protein, humanMinichromosome Maintenance ProteinsMultifunctional EnzymesPrimPol protein, humanRNA, Small InterferingSMARCAL1 protein, humanTranscription FactorsZRANB3 protein, human

Identifiers

PMID34645815
PMCPMC8514439
OpenAlexW3206632233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.